Gryphon Bio, Inc. is an early-stage company based in San Antonio, TX, dedicated to developing diagnostic-powered therapeutics for brain health. With over 20 years of brain proteomic research, their co-founders have made groundbreaking discoveries in brain-specific proteins and temporal blood biomarkers, paving the way for novel therapeutic targets. Gryphon Bio aims to improve the lives of patients by pioneering biologics with unique mechanisms of action and pharmacokinetic profiles, guided by virtual clinical trials and the development of artificial intelligence-based telemedicine solutions. Gryphon Bio's diversified pipeline of large molecule medicines, known as biologics, is inspired by nature's sequence of cellular and molecular events for central nervous system (CNS) repair. Their research focuses on developing diagnostic-powered therapeutics that bind to novel or de-risked therapeutic targets, with the goal of improving the care, management, and hospitalization of patients with CNS diseases. By leveraging temporal CNS blood biomarkers and innovative blood tests, Gryphon Bio aims to screen for diseases, predict outcomes, monitor disease progression, and inform key decisions related to recovery, hospitalization, and return-to-work. With a proven team of experts in drug development, business development, and CNS biomarker development, Gryphon Bio is poised to make a significant impact in the field of brain health.
Generated from the website